Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Array BioPharma, Oncothyreon deal

The companies partnered to develop and commercialize Array's ARRY-380 for cancer. The epidermal growth factor receptor 2 ( EGFR2; HER2; ErbB2;

Read the full 215 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE